Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.
Salmon-Céron D, Lassalle R, Pruvost A, Benech H, Bouvier-Alias M, Payan C, Goujard C, Bonnet E, Zoulim F, Morlat P, Sogni P, Pérusat S, Tréluyer JM, Chêne G; CORIST-ANRS HC1 Study Group. Salmon-Céron D, et al. Among authors: morlat p. Clin Infect Dis. 2003 May 15;36(10):1295-304. doi: 10.1086/374837. Epub 2003 May 9. Clin Infect Dis. 2003. PMID: 12746776 Clinical Trial.
Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001.
Thiébaut R, Chêne G, Jacqmin-Gadda H, Morlat P, Mercié P, Dupon M, Neau D, Ramaroson H, Dabis F, Salamon R; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Thiébaut R, et al. Among authors: morlat p. J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):380-6. doi: 10.1097/00126334-200307010-00013. J Acquir Immune Defic Syndr. 2003. PMID: 12843750
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.
Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, May T, Morlat P, Waldner A, Salamon R, Raffi F; Antiprotease Cohort (APROCO) Study Group. Duval X, et al. Among authors: morlat p. Clin Infect Dis. 2004 Jul 15;39(2):248-55. doi: 10.1086/422141. Epub 2004 Jul 1. Clin Infect Dis. 2004. PMID: 15307035
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, Costagliola D, May T, Chêne G; Mortality 2000 study group. Lewden C, et al. Among authors: morlat p. Int J Epidemiol. 2005 Feb;34(1):121-30. doi: 10.1093/ije/dyh307. Epub 2004 Nov 23. Int J Epidemiol. 2005. PMID: 15561752
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
Molina JM, Journot V, Morand-Joubert L, Yéni P, Rozenbaum W, Rancinan C, Fournier S, Morlat P, Palmer P, Dupont B, Goujard C, Dellamonica P, Collin F, Poizot-Martin I, Chene G; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team. Molina JM, et al. Among authors: morlat p. J Infect Dis. 2005 Mar 15;191(6):830-9. doi: 10.1086/428091. Epub 2005 Feb 10. J Infect Dis. 2005. PMID: 15717256 Clinical Trial.
463 results